Alpha-Fetoprotein Combined with Radiographic Tumor Burden Score to Predict Overall Survival after Liver Resection in Hepatocellular Carcinoma

We evaluated whether combining the radiographic tumor burden score (TBS) and alpha-fetoprotein (AFP) level could be used to stratify overall survival (OS) among hepatocellular carcinoma (HCC) patients after liver resection (LR). Patients who underwent LR for Barcelona Clinic Liver Cancer stage 0, A,...

Full description

Saved in:
Bibliographic Details
Published inCancers Vol. 15; no. 4; p. 1203
Main Authors Yen, Yi-Hao, Liu, Yueh-Wei, Li, Wei-Feng, Wang, Chih-Chi, Yong, Chee-Chien, Lin, Chih-Che, Lin, Chih-Yun
Format Journal Article
LanguageEnglish
Published Switzerland MDPI AG 01.02.2023
MDPI
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:We evaluated whether combining the radiographic tumor burden score (TBS) and alpha-fetoprotein (AFP) level could be used to stratify overall survival (OS) among hepatocellular carcinoma (HCC) patients after liver resection (LR). Patients who underwent LR for Barcelona Clinic Liver Cancer stage 0, A, or B HCC between 2011 and 2018 were enrolled. TBS scores were calculated using the following equation: TBS = (largest tumor size (in cm)) + (tumor number) . Among 743 patients, 193 (26.0%) patients had a low TBS (<2.6), 474 (63.8%) had a moderate TBS (2.6-7.9), and 75 (10.1%) had a high TBS (>7.9). Those with a TBS ≤ 7.9 and AFP < 400 ng/mL had a significantly better OS than those with a TBS > 7.9 and an AFP < 400 ng/mL ( = 0.003) or ≥ 400 ng/mL ( < 0.001). A multivariate analysis using TBS ≤ 7.9 and AFP < 400 ng/mL as the reference values showed that a TBS > 7.9 and an AFP < 400 ng/mL (hazard ratio (HR): 2.063; 95% confidence interval [CI]: 1.175-3.623; = 0.012) or ≥ 400 ng/mL (HR: 6.570; 95% CI: 3.684-11.719; < 0.001) were independent predictors of OS. In conclusion, combining radiographic TBSs and AFP levels could stratify OS among HCC patients undergoing LR.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
These authors contributed equally to this work.
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers15041203